Phosphagenics employees plead guilty over fraud
13 June, 2014A hearing into the alleged fraud against Phosphagenics has resulted in two men pleading guilty to issuing false invoices worth millions of dollars.
Biotech survey shows advanced manufacturing heading overseas
12 June, 2014The annual Biotechnology Industry Position Survey (2014) shows a worrying trend: advanced manufacturing associated with this industry of the future is following traditional manufacturing and there has been a sharp increase in the number of companies heading overseas.
UWA Professor named WA's Chief Scientist
11 June, 2014 by Dylan Bushell-EmblingMedical research luminary Professor Peter Klinken has taken the role of Western Australia's Chief Scientist and aims to change the state's research focus from oil and gas mining to biotechnology.
Outcome on employee share schemes expected mid-June
10 June, 2014Treasury has confirmed that issues raised in submissions to its review of 'employee share schemes (ESS) and start-ups' will be considered by the Prime Minister's taskforce established to develop a National Industry Investment and Competitiveness Agenda, which is expected to be delivered in the coming weeks.
First burns patient treated in NovoSorb BTM trial
06 June, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) revealed that the first burns patient enrolled in a clinical trial of its NovoSorb BTM has been successfully treated and is out of intensive care.
Starpharma making progress with clinical trials
06 June, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has dosed the first group of patients for a phase I trial of DEP docetaxel in solid tumours and commenced final preparations for a phase III trial of VivaGel for the prevention of BV recurrence.
ResMed wins import ban against Taiwan's APEX
05 June, 2014 by Dylan Bushell-EmblingAn ITC judge has ruled that two products from Taiwanese manufacturer APEX still infringe on ResMed (ASX:RMD) patents and cannot be imported or sold in the US.
New guidance for ASX-listed companies
05 June, 2014Two new guidance documents are now available to support ASX-listed companies. The third edition of the ASX's Corporate Governance Principles and Recommendations (CGPR) comes into effect on 1 July after a recent review, and ASIC has released guidance to ASX-listed entities on analyst and investor briefings.
AusMedtech responds to the TGA's review of the low value turnover exemption scheme
03 June, 2014AusMedtech has told the TGA's review that it is concerned that only a very low number of small businesses are taking advantage of the low value turnover exemption (LVT) scheme, despite the eligibility of their products.
Benitec treats first patient in HCV trial
02 June, 2014 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has commenced a phase I/IIa trial of ddRNAi-based therapeutic TT-034, marking the first time the treatment candidate has been used in humans.
Cochlear to launch new implant in EU in June
02 June, 2014 by Dylan Bushell-EmblingCochlear (ASX:COH) will this month launch the first in its Nucleus Profile line of implants - the successor to its Cl500 series - in Europe.
Mesoblast accelerates Singapore manufacturing plans
30 May, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has secured economic incentives in Singapore, as part of efforts to prepare for commercial manufacturing of Prochymal, an allogenic stem cell product awaiting approval in GVHD.
Orthocell launches $8m IPO
30 May, 2014 by Dylan Bushell-EmblingWA's Orthocell has commenced an $8m IPO, as it seeks to raise funds to expand the reach of its two TGA-approved regenerative medicine products and complete development of a third.
Joint position to grow Australia's biopharmaceutical industry
29 May, 2014AusBiotech and Medicines Australia have provided a joint statement to the Minister for Industry, the Hon Ian Macfarlane, proposing steps that the federal government could take to build a stronger biopharmaceutical industry in Australia.
Minomic to seek CE Mark for prostate cancer test
28 May, 2014 by Dylan Bushell-EmblingMinomic International announced that it aims to complete the process of applying for a CE Mark for prostate cancer diagnostics test MiSat ELISA by the fourth quarter.
